Cantel Medical Corp. (CMD) Reached 52-Week High at $127.67

May 16, 2018 - By Noel Courtney

Cantel Medical Corp. (NYSE:CMD) having $127.67 price per share and $139.16 price target broke into 52 week high. It was announced on May, 16 by The company has $5.33B MC. The valuation of NYSE:CMD can change by $479.34M if our $139.16 price target is broke into.

Ticker’s shares touched $127.67 during the last trading session after 2.23% change.Currently Cantel Medical Corp. is uptrending after 41.41% change in last May 16, 2017. CMD has 161,870 shares volume. The stock outperformed the S&P 500 by 29.86%.

Cantel Medical Corp. (NYSE:CMD)’s earnings release is expected by WallStreet on May, 31, according to Faxor. Analysts have expectation on stock’s earnings per share of $0.60. That’s up 17.65 % from last year’s $0.51 earnings per share. If $0.60 is reported, CMD’s profit will reach $25.03M for 53.20 P/E. 1.69 % EPS growth is what Wall Street’s predicts after $0.59 reported EPS last quarter.

There’s a significant Cantel Medical Corp. (NYSE:CMD) news released by It’s a report titled: “Jim Cramer Weighs In On Align Technology, Berkshire Hathaway, Symantec And More” on May 15, 2018.

Cantel Medical Corp. provides infection prevention services and products for the healthcare market worldwide.The firm is valued at $5.33 billion. The firm operates through four divisions: Endoscopy, Water Purification and Filtration, Healthcare Disposables, and Dialysis.The P/E ratio is 59.22. The Endoscopy segment offers automated endoscope reprocessing systems; detergents; leak testing and manual cleaning products; storage cabinets; transport systems; mobile medical carts; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid and flexible endoscopes, and other instrumentation; cleaning and disinfecting reusable components used in gastrointestinal endoscopy procedures; and technical maintenance services.

Cantel Medical Corp. (NYSE:CMD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: